一品红(300723.SZ)：馥感啉颗粒获药物临床试验批准

Group 1 - The core point of the article is that Yipinhong Pharmaceutical's subsidiary has received approval for clinical trials of a new drug aimed at treating adult patients with Qi deficiency cold [1] Group 2 - Yipinhong Pharmaceutical's subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has been granted a clinical trial approval notice by the National Medical Products Administration [1] - The drug being tested is called Fuganling Granules, which is intended for use in adults suffering from Qi deficiency cold [1]